In 2026, the U.S. Food and Drug Administration (FDA) approved 29 entirely new medicines that had never been available to American patients before. Each one represents a breakthrough — a treatment option that simply did not exist until researchers figured out how to make it work.
These novel drug approvals covered a remarkably wide range of conditions. Among them: Simtriyocentanafadine (approved July 24) became the first new option for attention-deficit hyperactivity disorder in years. Idvynsodoravirine and islatravir (April 20) offered people living with HIV a completely new combination pill to replace their existing antiretroviral regimen. Awiqli insulin icodec-abae (March 26) gave adults with type 2 diabetes a new tool for controlling blood sugar.
Cancer patients gained several new options. Jideytrozidesamtinib (July 22) targets ROS1-positive non-small cell lung cancer, while Revtorpykgedatolisib (July 14) addresses a specific type of breast cancer. Lifyorlirelacorilant (March 25) became available for platinum-resistant ovarian cancer, a condition that had few effective treatments.
Some approvals addressed rare diseases that previously had no treatments at all. Avlayah tividenofusp alfa-eknm (March 24) treats Hunter syndrome, a rare genetic disorder that affects children. Zycubo copper histidinate (January 12) became the very first treatment for Menkes disease, a devastating condition that impairs how the body processes copper. Yuviwelnavepegritide (February 27) helps children with achondroplasia, the most common form of dwarfism, grow taller.
Other notable approvals included Bysantimilsaperidone for schizophrenia and bipolar disorder, Adqueydifamilast for mild-to-moderate eczema, and Cypsedocipepofol for inducing general anesthesia during surgery.
The FDA's Center for Drug Evaluation and Research (CDER) maintains a database called Drugs@FDA where anyone can look up all approved medicines. Each of these 29 drugs underwent rigorous clinical trials to prove they were safe and effective before receiving approval.
For patients and families facing difficult diagnoses, these approvals represent real, tangible hope. In just six months of 2026, nearly thirty diseases now have treatment options that did not exist before.
